Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

(2017) Athanasios D Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Observations following discontinuation of long-term denosumab therapy

(2017) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report

(2016) Olivier Lamy et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2015) Dennis M. Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

(2015) B. Aubry-Rozier et al.   OSTEOPOROSIS INTERNATIONAL

Multiple clinical vertebral fractures following denosumab discontinuation

(2015) A. D. Anastasilakis et al.   OSTEOPOROSIS INTERNATIONAL

Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics

(2015) A. W. Popp et al.   OSTEOPOROSIS INTERNATIONAL

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

(2012) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE